Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Invested Capital (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Invested Capital readings, the most recent being $83.0 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 37.74% to $83.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $83.0 million, a 37.74% decrease, with the full-year FY2025 number at $83.0 million, down 37.74% from a year prior.
  • Invested Capital hit $83.0 million in Q4 2025 for Avalo Therapeutics, down from $91.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $133.4 million in Q4 2024 to a low of -$112.5 million in Q1 2024.
  • Median Invested Capital over the past 5 years was $17.9 million (2023), compared with a mean of $27.3 million.
  • The widest YoY moves for Invested Capital: up 1726.29% in 2024, down 1695.79% in 2024.
  • Avalo Therapeutics' Invested Capital stood at $23.1 million in 2021, then plummeted by 147.29% to -$10.9 million in 2022, then skyrocketed by 166.92% to $7.3 million in 2023, then soared by 1726.29% to $133.4 million in 2024, then tumbled by 37.74% to $83.0 million in 2025.
  • The last three reported values for Invested Capital were $83.0 million (Q4 2025), $91.5 million (Q3 2025), and $104.9 million (Q2 2025) per Business Quant data.